Project Details
Description
RESPIR-102: A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus? Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection
| Status | Active |
|---|---|
| Effective start/end date | 9/1/23 → 9/1/25 |
Funding
- RESPIRION PHARMACEUTICALS PTY LTD
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.